New York State Common Retirement Fund reduced its stake in shares of Zoetis Inc. (NYSE:ZTS) by 16.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,375,370 shares of the company’s stock after selling 280,462 shares during the quarter. New York State Common Retirement Fund owned about 0.28% of Zoetis worth $85,796,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of ZTS. CGOV Asset Management grew its stake in Zoetis by 2.7% during the 1st quarter. CGOV Asset Management now owns 169,605 shares of the company’s stock worth $12,059,000 after buying an additional 4,405 shares during the last quarter. UBS Asset Management Americas Inc. grew its stake in Zoetis by 5.0% during the 1st quarter. UBS Asset Management Americas Inc. now owns 1,942,609 shares of the company’s stock worth $103,677,000 after buying an additional 91,962 shares during the last quarter. Meadow Creek Investment Management LLC grew its stake in Zoetis by 24.7% during the 1st quarter. Meadow Creek Investment Management LLC now owns 7,344 shares of the company’s stock worth $392,000 after buying an additional 1,456 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in Zoetis by 28.9% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 36,493 shares of the company’s stock worth $1,948,000 after buying an additional 8,184 shares during the last quarter. Finally, 12th Street Asset Management Company LLC grew its stake in Zoetis by 6.1% during the 1st quarter. 12th Street Asset Management Company LLC now owns 176,655 shares of the company’s stock worth $9,428,000 after buying an additional 10,225 shares during the last quarter. Hedge funds and other institutional investors own 93.20% of the company’s stock.
Shares of Zoetis Inc. (NYSE:ZTS) traded down 0.84% on Tuesday, reaching $64.65. The company had a trading volume of 382,525 shares. The firm has a market cap of $31.62 billion, a P/E ratio of 36.55 and a beta of 1.02. The company has a 50-day moving average price of $62.37 and a 200-day moving average price of $59.56. Zoetis Inc. has a one year low of $46.86 and a one year high of $65.83.
Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period last year, the firm earned $0.49 EPS. On average, analysts expect that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “New York State Common Retirement Fund Sells 280,462 Shares of Zoetis Inc. (ZTS)” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://sportsperspectives.com/2017/09/19/new-york-state-common-retirement-fund-sells-280462-shares-of-zoetis-inc-zts.html.
A number of brokerages recently commented on ZTS. BidaskClub upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, September 12th. Cowen and Company set a $70.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Monday, July 17th. Cantor Fitzgerald reissued a “buy” rating and issued a $75.00 price target on shares of Zoetis in a research note on Wednesday, September 6th. Deutsche Bank AG reissued a “buy” rating and issued a $65.00 price target (up previously from $62.00) on shares of Zoetis in a research note on Monday, July 17th. Finally, Zacks Investment Research raised Zoetis from a “hold” rating to a “buy” rating and set a $71.00 price target for the company in a research note on Tuesday, June 20th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $65.44.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.